Cleared Traditional

K221826 - BD BBL Sensi-Disc Cefiderocol 30ug (FDC-30) (FDA 510(k) Clearance)

Dec 2022
Decision
181d
Days
Class 2
Risk

K221826 is an FDA 510(k) clearance for the BD BBL Sensi-Disc Cefiderocol 30ug (FDC-30). This device is classified as a Susceptibility Test Discs, Antimicrobial (Class II - Special Controls, product code JTN).

Submitted by Becton, Dickinson and Company (Sparks, US). The FDA issued a Cleared decision on December 21, 2022, 181 days after receiving the submission on June 23, 2022.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.1620.

Submission Details

510(k) Number K221826 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 23, 2022
Decision Date December 21, 2022
Days to Decision 181 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code JTN — Susceptibility Test Discs, Antimicrobial
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.1620

Similar Devices — JTN Susceptibility Test Discs, Antimicrobial

All 7
HardyDisk AST Cefiderocol 30µg (FDC30)
K253105 · Hardy Diagnostics · Nov 2025
HardyDisk AST Gepotidacin 10µg (GEP10)
K250956 · Hardy Diagnostics · Jun 2025
HardyDisk Aztreonam/Avibactam 30/20µg (AZA50)
K250454 · Hardy Diagnostics · May 2025
HardyDisk AST Cefiderocol 30µg (FDC30)
K241060 · Hardy Diagnostics · Jul 2024
HardyDisk AST Sulbactam/Durlobactam 10/10µg (SUD20)
K231568 · Hardy Diagnostics · Jul 2023
BD BBL™ Sensi-Disc™ Lefamulin 20µg (LMU-20)
K230651 · Becton, Dickinson and Company · Jun 2023